Do You Believe in the Growth Prospects of Soleno Therapeutics (SLNO)?

1 week ago 6

Soumya Eswaran

Tue, January 6, 2026 astatine 7:00 AM CST 2 min read

TimesSquare Capital Management, an equity concern absorption company, released its “U.S. Small Cap Growth Strategy” third-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. During the quarter, the money returned 2.26% (gross) and 2.01% (net), compared to the Russell 2000 Growth Index’s 12.19% return. During the quarter, each plus classes but fixed income extracurricular the U.S. posted affirmative returns. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its third-quarter 2025 capitalist letter, TimesSquare Capital U.S. Small Cap Growth Strategy highlighted stocks specified arsenic Soleno Therapeutics, Inc. (NASDAQ:SLNO). Soleno Therapeutics, Inc. (NASDAQ:SLNO) is simply a clinical-stage biopharmaceutical company. The one-month instrumentality of Soleno Therapeutics, Inc. (NASDAQ:SLNO) was -9.58%, and its shares mislaid 2.16% of their worth implicit the past 52 weeks. On January 5, 2026, Soleno Therapeutics, Inc. (NASDAQ:SLNO) banal closed astatine $45.22 per share, with a marketplace capitalization of $2.429 billion.

TimesSquare Capital U.S. Small Cap Growth Strategy stated the pursuing regarding Soleno Therapeutics, Inc. (NASDAQ:SLNO) successful its 3rd 4th 2025 capitalist letter:

"We felt otherwise astir biopharma developer Soleno Therapeutics, Inc. (NASDAQ:SLNO) and added to our holdings arsenic its shares pulled backmost by -19%. A abbreviated seller’s study questioned the information of Soleno’s Vykat attraction for Prader-Willi Syndrome, a generic upset starring to unnaturally aggravated and unsatiable hunger. We spoke with the company’s absorption arsenic good arsenic world clinicians and judge the carnivore lawsuit allegations are inaccurate oregon hyperbolic.

Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 58 hedge money portfolios held Soleno Therapeutics, Inc. (NASDAQ:SLNO) astatine the extremity of the 3rd quarter, up from 52 successful the erstwhile quarter. In Q3 2025, Soleno Therapeutics, Inc.'s (NASDAQ:SLNO) nett gross much than doubled to $66 cardinal from Q2 2025. While we admit the imaginable of Soleno Therapeutics, Inc. (NASDAQ:SLNO) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

In another article, we covered Soleno Therapeutics, Inc. (NASDAQ:SLNO) and shared the database of inexpensive healthcare stocks to bargain heading into 2026. In addition, delight cheque retired our hedge money capitalist letters Q3 2025 page for much capitalist letters from hedge funds and different starring investors.